Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans

By Luigi Fontana, J. C. Eagon, M. Trujillo, P. Scherer, S. Klein. Diabetes, 2007

1,436 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/dc8f425a9a03f2dc87e050f764c92d7f9d0511c0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Herbert Tilg
2. A. Moschen
3. Mitchell A. Lazar
4. B. Spiegelman
5. E. Rosen

In Epidemiology

1. Herbert Tilg
2. S. Klein
3. A. Okunade
4. B. Patterson
5. A. Moschen
6. Alexander Sakers
7. Mirian Krystel De Siqueira
8. P. Seale

In Physiology

1. Herbert Tilg
2. M. Qatanani
3. Alexander Sakers
4. Mirian Krystel De Siqueira
5. P. Seale
6. S. Fried
7. Mitchell A. Lazar
8. H. Kwon

Citations in the corpus

• Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. (2008, background): “study in extremely obese patients indicates that visceral fat is the main contributor of plasma IL-6 concentration.(31) It is therefore conceivable that viscerally produced adipocytokines directly influ-”
• Inflammatory Mechanisms in the Regulation of Insulin Resistance (2008, background): “Visceral fat has been demonstrated as an important site for IL-6 secretion in humans (17).”
• Obesity and inflammation: the linking mechanism and the complications (2016, background): “It has been calculated that one third of total circulating concentrations of IL-6 originate from adipose tissue [18].”
• Obesity and Cancer: The Role of Dysfunctional Adipose Tissue (2009, background): “contribute to systemic inflammation as seen in abdominal obesity (38, 39).”
• Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity (2009, background): “secretion rates of most adipokines from VAT are probably not greater than the secretion rates from subcutaneous adipose tissue (19).”
• Adipose tissue plasticity in health and disease (2022, background): “lower in the portal compared with systemic circulation of severely obese subjects (Fontana et al., 2007).”
• Nonalcoholic fatty liver disease: pathology and pathogenesis. (2010, background): “IL-6 is an adipocytokine associated with NALFD and obesity that is secreted in larger amounts by visceral fat compared to subcutaneous fat in obese adults (117).”
• Mechanisms of obesity-associated insulin resistance: many choices on the menu. (2007, background): “Other molecular differences between visceral and peripheral fat may also contribute to insulin resistance associated with visceral adiposity (Gesta et al. 2006; Fontana et al. 2007).”
• Adipokines Mediate Inflammation and Insulin Resistance (2013, background): “In contrast, visceral adipose tissue is positively associated with risk of insulin resistance and shows higher monocytes infiltration and IL-6 production than subcutaneous adipose tissue to induce inflammation in obese subjects (Cancello et al., 2006; Fontana et al., 2007).”
• Adipose Tissue Heterogeneity: Implication of depot differences in adipose tissue for Obesity Complications (2012, background): “Higher IL-6 and lower leptin levels in portal vein compared to peripheral artery have been reported in vivo (Fontana et al. 2007).”